Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AgenusFRA:AJ8 -3.94%46 Days Payable is 401.32 as of Jun. 2026, which is 832% above its 10-year median of 43.06. GuruFocus rates FRA:AJ8 with a GF Score™ of 46/100 and a GF Value™ of €3.22 (Significantly Overvalued). The stock has 12 warning signs investors should review. Among 702 Biotechnology companies, Agenus ranks better than 78.06% on this metric.
Agenus's average Accounts Payable for the
three
months ended in Jun. 2026 was €56.3 Mil. Agenus's Cost of Goods Sold for the
three
months ended in Jun. 2026 was €12.8 Mil.
Hence, Agenus's Days Payable for the
three
months ended in Jun. 2026 was 401.32.
The historical rank and industry rank for Agenus's Days Payable or its related term are showing as below:
FRA:AJ8'
s Days Payable Range Over the Past 10 Years
Min: 19.06 Med: 43.06 Max: 466.48
Current: 466.48
During the past 13 years, Agenus's highest Days Payable was 466.48. The lowest was 19.06. And the median was 43.06.
FRA:AJ8's Days Payable is ranked better than 78.06% of 702
companies
in the Biotechnology industry
Industry Median: 110.69
vs FRA:AJ8: 466.48
Agenus's Days Payable
increased
from Jun. 2025 (241.95) to Jun. 2026 (401.32).
It may suggest that Agenusdelayed paying its suppliers.
The historical data trend for Agenus's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:AJ8 vs FULC, IRD, TTRX: Days Payable Comparison
For the Biotechnology subindustry, Agenus's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agenus Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Agenus's Days Payable distribution charts can be found below:
* The bar in red indicates where Agenus's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Agenus's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agenus (FRA:AJ8) has a Days Payable of 401.32 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Agenus and its competitors. This is 832% above median its historical median of 43.06. Over the past decade, Agenus' Days Payable has ranged from 19.06 to 466.48. According to the industry distribution chart, Agenus ranks #154 out of 702 companies in the Biotechnology industry, placing it in the top 21.9%.
Is Agenus' Days Payable too high?
Agenus' current Days Payable of 401.32 is 832% above median its 10-year median of 43.06. Over the past 10 years, this metric has ranged from a low of 19.06 to a high of 466.48. The Biotechnology industry median Days Payable is 110.69. Agenus' value of 401.32 is 262.6% above this industry median. Based on the distribution chart, Agenus ranks #154 out of 702 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Agenus has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Agenus' Days Payable compare to FULC and IRD?
According to the Biotechnology industry distribution chart, Agenus ranks #154 out of 702 companies for Days Payable. This places Agenus in the top 22% of its industry — outperforming the majority of peers. The industry median Days Payable is 110.69. Agenus' value of 401.32 is 262.6% above this benchmark. Historically, Agenus' own Days Payable has ranged from 19.06 to 466.48 over the past decade. While the company's 10-year median is 43.06 vs. the industry median of 110.69, Agenus has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 110.69, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Agenus's current Days Payable of 401.32 is 262.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Agenus and its competitors. For the Biotechnology industry, the median Days Payable is 110.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Agenus's current Days Payable is 401.32, which is 832% above median its own 10-year median of 43.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agenus stock overvalued right now?
Based on GuruFocus' analysis, Agenus (FRA:AJ8) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.22, compared to a current price of €6.10 — trading 89.4% above its estimated fair value. The current Days Payable is 401.32, which is 832% above median its 10-year median of 43.06 and 262.6% above the Biotechnology industry median of 110.69. Agenus' overall GF Score™ is 46/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Agenus (FRA:AJ8), the current Days Payable is 401.32 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agenus (FRA:AJ8) Overvalued in 2026?
Based on GuruFocus' analysis, Agenus stock appears to be overvalued.
The current stock price of €6.10 is trading 89.4% above its estimated GF Value™ of €3.22.
GuruFocus considers Agenus to be Significantly Overvalued.
Key valuation signals for FRA:AJ8:
Days Payable: 401.32 (832% above median its 10-year median of 43.06)
GF Value™: €3.22 vs. price of €6.10 (89.4% above fair value)
Industry Position: 262.6% above the Biotechnology median (#154 of 702)
No single metric tells the full story. See the FRA:AJ8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
46GF Score
Get the complete analysis for FRA:AJ8
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AJ8 has been successfully added to your 
